Navigation Links
Verenium Appoints Holger Liepmann To Its Board Of Directors
Date:2/26/2013

SAN DIEGO, Feb. 26, 2013 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that Michael Zak will be leaving its Board of Directors effective March 31, 2013, and that Holger Liepmann will be appointed to its Board of Directors, also effective March 31, 2013.

(Logo: http://photos.prnewswire.com/prnh/20120924/MM79973LOGO)

"I am pleased to welcome Holger to Verenium's Board of Directors, as his extensive global operations experience, which included very successful product launches in the pharmaceutical, hospital and nutritional arena, will prove especially important as we focus on growing our commercial business and further diversifying our product portfolio," said Dr. James Cavanaugh , Chairman of the Board of Verenium.  "I'd also like to thank Michael Zak for his many years of service to Verenium."

Mr. Liepmann retired two years ago from Abbott Laboratories, a leading global health care company, where he spent 25 years in various positions gaining progressively greater responsibilities in the company throughout his career. Most recently, he served as Executive Vice President of Global Nutrition where he was responsible for all facets of the company's second largest business with sales exceeding $5.5 billion.  In this role, Mr. Liepmann helped the Global Nutrition group grow market share globally, including becoming the market leader in the U.S. and significantly expanding international sales.  Prior to that, he served as Executive Vice President of Abbott's Pharmaceutical Products Group,
'/>"/>

SOURCE Verenium Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Verenium To Sponsor The Renewable Fuels Association 18th Annual National Ethanol Conference
2. Novus International And Verenium Announce Important Progress In The Development Of Novel Enzymes For Animal Health & Nutrition
3. Verenium Announces $22.5 Million, Five-Year Secured Financing
4. Verenium Corporation To Announce Third Quarter 2012 Financial Results
5. Verenium Reports Financial Results For The Second Quarter And Six Months Ended June 30, 2012
6. Verenium Corporation To Announce Second Quarter 2012 Financial Results
7. Verenium Announces EPA Authorization To Market Its Next-Generation Enzyme Breaker For Hydraulic Fracturing
8. Verenium Corporation And Alexandria Real Estate Equities, Inc. Celebrate The Grand Opening Of A New State-of-the-art Biotechnology Facility
9. Verenium Corporation Named One Of The 2012 Best Places to Work in San Diego
10. Verenium Corporation To Announce First Quarter 2012 Financial Results
11. Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Sciences, Inc. (OTCQB: GBLX), a medical cannabis research and development ... marijuana dispensary locations in Las Vegas, Nevada ... Clark County, Nevada dispensary for which the company ... GrowBLOX Sciences, CEO Craig Ellins stated, "We ... in the City of Las Vegas . ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 a2z Inc. ... ChirpE Mobile App, AACC Pathfinder, in its 2014 ... AACC’s annual meeting is planned for July 29-31, 2014 ... place to be to connect with global leaders in ... management, and other areas of breaking science in laboratory ...
(Date:7/22/2014)... 2014 Even within a phylum so full of mean ... other arthropods for its cruelty -- at least to crickets. ... fly is a most predatory sort of parasite. It swoops ... smear of larvae, and leaves its wicked brood to invade, ... None of this would be possible without the fly,s ability ...
(Date:7/22/2014)... July 22, 2014 Nuclear reactors are ... produced by controlled fission chain reaction in nuclear reactors ... is used to drive a power- generating turbine. Currently ... the world’s total electricity production. Nuclear reactor market is ... construction, planned and proposed nuclear reactor projects. , Early ...
Breaking Biology Technology:GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 3
... Oct. 12 Spherix Incorporated (Nasdaq: SPEX ... metabolic syndrome and atherosclerosis; and providers of technical and ... companies, today announced the close of previously reported agreements ... B Convertible Preferred Stock and warrants to purchase shares ...
... 12 US Oncology, Inc., the nation,s ... enrolled the 1,000th patient in a Phase I clinical ... Phase I clinical trials present special challenges, including increased ... trial designs, and some first-in-human trials, making Phase I ...
... SCOTTSDALE, AZ, Oct. 12 /PRNewswire/ - Dynamic Ventures ... the Editorial Board of Standard and Poor,s ("S&P") ... Records Market Access Program. Standard & Poor,s Corporation ... on U.S. and international public companies by investors ...
Cached Biology Technology:Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants 2Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants 3US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 2US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 3US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 4US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 5Dynamic Ventures Corporation's Information To Be Available Through Standard & Poor's Market Access Program 2
(Date:7/23/2014)... are packed with healthful compounds, and now lab tests ... as prescription anti-diabetic medication, scientists report. In their new ... Food Chemistry , they found that how the herbs ... which compounds contribute the most to this promising trait. ... that in 2012, type-2 diabetes affected more than 8 ...
(Date:7/23/2014)... Basement membrane degradation and blood-brain barrier damage ... and brain functioning. Matrix metalloproteinase-9 is able ... basement membrane around cerebral blood vessels and ... Huilian Hou and colleagues from the First ... Jiaotong University, China induced cerebral infarction in ...
(Date:7/23/2014)... hippocampal region of the brain is important ... However, the underlying mechanisms are unclear. Dr. ... China monitored the activity of hippocampal neurons ... the mechanisms underlying the neuronal responses. Somatosensory ... changed local field potentials into theta rhythm-dominated ...
Breaking Biology News(10 mins):
... Attendance on Demand,web-hosted employee time and attendance service ... time clock. The unique data,collection device is Internet-ready, ... the web hosted employee time tracking system,Attendance on ... complex set-up,needed., The HP WebNet, available exclusively ...
... developed a potentially powerful new tool in the fight ... diseases, including blindness, in 40 million children annually, and ... in developing countries. This tool consists of ... corn that will enable developing countries to identify and ...
... species are those that occur outside their natural range ... They can be plants, animals or microorganisms that are ... through tourism, travel or trade, or when domestic animals ... to the rising cost of invasive species on a ...
Cached Biology News:Web-Hosted Attendance on Demand(R) Introduces Innovative Web Time Clock 2New way to produce high-vitamin corn could improve nutrition in developing countries 2New way to produce high-vitamin corn could improve nutrition in developing countries 3Scientists call for urgent research into 'real' impacts of invasive species 2Scientists call for urgent research into 'real' impacts of invasive species 3
Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
Parathyroid Hormone Receptor 2 [PTHR2]...
... Desalt Spin Columns contain a proprietary high-performance ... exceptional desalting and protein-recovery characteristics compared to ... low as 25 g/ml of protein can ... > 95% retention of salts and other ...
Biology Products: